GlassScriptPhysician profile
Steven E Yordy
NPI 1710947197
$16,954.76
in general payments reported to CMS, 2019-2025
44 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,469 · 2020: $2,088 · 2021: $3,360 · 2022: $2,777 · 2023: $2,635 · 2024: $2,386 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,261.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,724.98 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $2,484.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,688.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,300.82 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $1,280.97 | 2019-2025 | |
| Amgen INC. | $1,001.65 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $941.81 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $758.54 | 2019-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $610.60 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $495.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $444.96 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $378.43 | 2019-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.79 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $316.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $223.20 | 2019-2025 | Camzyos, Eliquis |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $218.25 | 2020-2025 | |
| Radius Health, INC. | $211.04 | 2019-2025 | Tymlos, Binosto |
| Merck Sharp & Dohme LLC | $172.92 | 2019-2022 | |
| Amarin Pharma, INC. | $162.16 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $140.64 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $136.79 | 2021 | |
| Biodelivery Sciences International, INC. | $85.79 | 2020-2021 | |
| Sanofi Pasteur INC. | $85.71 | 2019-2025 | |
| Dexcom, INC. | $82.99 | 2022-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $72.41 | 2021-2023 | Seglentis |
| Abbott Laboratories | $66.15 | 2022-2024 | Freestyle Libre 3 |
| Eisai INC. | $54.81 | 2021-2022 | |
| Genentech USA, INC. | $53.96 | 2019-2021 | |
| Biogen, INC. | $50.73 | 2021-2022 | |
| Mylan Specialty L.P. | $48.62 | 2019-2023 | Yupelri |
| Verona Pharma, INC. | $40.56 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $31.15 | 2019-2022 | |
| Indivior INC. | $30.18 | 2024-2025 | Sublocade |
| Daiichi Sankyo INC. | $25.76 | 2019-2023 | Injectafer |
| Kyowa Kirin, INC. | $23.17 | 2024 | Crysvita |
| Axsome Therapeutics, INC. | $21.63 | 2023 | Auvelity |
| Bausch Health US, LLC | $20.66 | 2021 | |
| Braeburn INC. | $17.30 | 2025 | Brixadi |
| Redhill Biopharma INC. | $16.99 | 2020 | |
| Cequr Corporation | $13.42 | 2025 | Cequr Simplicity |
| Lundbeck LLC | $13.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yordy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.